

P20797.A04

1631

O I P E
JUL 03 2002
TRADEMARK OFFICE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: A. ITAI et al.

Group Art Unit: 2764

Serial No.: 09/810,670
(National Stage of PCT/JP96/03325)

Examiner: Unknown

Filed: March 19, 2001
(International Filing Date November 13, 1996)

9
Plunkett
8/5/02

For: DESIGN METHOD OF PHYSIOLOGICALLY ACTIVE COMPOUND

INFORMATION DISCLOSURE STATEMENT

RECEIVED

Commissioner of Patents and Trademarks
Washington, DC 20231

JUL 12 2002

TECH CENTER 1600/2900

Sir:

Subsequent to the Informaion Disclosure Statement filed November 14, 2001, and in accordance with Applicants' duty of disclosure under 37 C.F.R. §1.56, Applicants hereby submit the following Information Disclosure Statement under 37 C.F.R. §§ 1.97 and 1.98, and in conformance with MPEP §§ 609 and 2001.06(b).

Applicants hereby bring the following information which was cited in the Supplementary European Search Report mailed April 2, 2002 issued in connection with International Application No. PCT/JP96/03866 (copy enclosed) to the attention of the Examiner in charge of the above-identified application. The Examiner is invited to review this Report to see the relevance indicated during international examination with respect to the documents cited therein.

Martin, Yvonne C., Database accension no: 114:80616 CA XP002196005;

Moon, J., and Howe, W., Proteins:, Struct., Funct., Genet. 11(4), pp. 314-328 (1991);

Boehm, Hans J., Database accenssion no: 119:66291 CA XP002196006;

Boehm, Hans J., J. Computer-Aided Mol. Des. 6, pp. 61-78 (1992).

Copies of the above-noted documents are enclosed together with a duly completed form PTO-1449. The Examiner is accordingly requested to consider each of these documents, and to

P20797.A04

make them of record in this application by initialing in the appropriate spaces on the Form PTO-1449. Applicant respectfully requests that the Examiner include a copy of the initialed Form PTO-1449 with the next communication from the U.S. Patent and Trademark Office.

Additionally, the Examiner's attention is directed to the following commonly assigned co-pending U.S. patent application, a copy of which is enclosed:

U.S. Application Serial No. 10/022,275, filed December 12, 2001, in the name of ITAI et al., entitled, "Method of Searching Novel Ligand Compounds from Three-Dimensional Structure Database."


Applicants note that a copy of this application is attached hereto. The Examiner is invited to review the file wrapper of these U.S. patent applications, including the specifications, claims, disclosure statements, and documents cited therein, at the U.S. Patent and Trademark Office.

Applicants note that this disclosure statement is being filed after three months from the filing date, but is being filed prior to receipt of a first action on the merits, whereby a fee should not be necessary for consideration of the disclosure statement. However, if an Office Action is crossing this paper in the mail or for any reason a fee is required for consideration of this disclosure statement, including any fee under 37 C.F.R. 1.17(p), the Commissioner is authorized to charge any necessary fee to Deposit Account No. 19-0089.

P20797.A04

If the Examiner has any questions, the Examiner is respectfully invited to contact the undersigned at the below-listed telephone number.

Respectfully submitted,
A. ITAI et al.



Bruce H. Bernstein
Reg. No. 29,027

Reg No.
31,296

June 18, 2002
GREENBLUM & BERNSTEIN, P.L.C.
1941 Roland Clarke
Reston, VA 20191
(703) 716-1191

[illegible]